BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 34932012)

  • 21. Opioid use and harms associated with a sustained-release tapentadol formulation: a postmarketing study protocol.
    Peacock A; Larance B; Farrell M; Cairns R; Buckley N; Degenhardt L
    BMJ Open; 2018 Mar; 8(3):e020006. PubMed ID: 29574444
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Machine Learning Approach for the Detection and Characterization of Illicit Drug Dealers on Instagram: Model Evaluation Study.
    Li J; Xu Q; Shah N; Mackey TK
    J Med Internet Res; 2019 Jun; 21(6):e13803. PubMed ID: 31199298
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bone fractures in patients using tapentadol or oxycodone: an exploratory US claims database study.
    Morlion BJ; Margarit C; Wild I; Karra R; Liedgens H; Sohns M; Finco G
    Pain Manag; 2021 Jan; 11(1):39-47. PubMed ID: 32996831
    [No Abstract]   [Full Text] [Related]  

  • 24. [Undesired side effects of tapentadol in comparison to oxycodone. A meta-analysis of randomized controlled comparative studies].
    Merker M; Dinges G; Koch T; Kranke P; Morin AM
    Schmerz; 2012 Feb; 26(1):16-26. PubMed ID: 22366930
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomised, placebo-controlled trial comparing the effects of tapentadol and oxycodone on gastrointestinal and colonic transit in healthy humans.
    Jeong ID; Camilleri M; Shin A; Iturrino J; Boldingh A; Busciglio I; Burton D; Ryks M; Rhoten D; Zinsmeister AR
    Aliment Pharmacol Ther; 2012 May; 35(9):1088-96. PubMed ID: 22348605
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of opioid doctor shopping for tapentadol and oxycodone: a cohort study.
    Cepeda MS; Fife D; Vo L; Mastrogiovanni G; Yuan Y
    J Pain; 2013 Feb; 14(2):158-64. PubMed ID: 23253635
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of opioid prescribing upon hospital discharge in patients receiving tapentadol versus oxycodone following orthopaedic surgery.
    Wang X; Tay HP; Narayan SW; Penm J; Patanwala AE
    Int J Clin Pharm; 2021 Dec; 43(6):1602-1608. PubMed ID: 34089144
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Incidence of Delirium With Different Oral Opioids in Previously Opioid-Naive Patients.
    Sugiyama Y; Tanaka R; Sato T; Sato T; Saitoh A; Yamada D; Shino M
    Am J Hosp Palliat Care; 2022 Oct; 39(10):1145-1151. PubMed ID: 35045754
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparing rates and characteristics of ambulance attendances related to extramedical use of pharmaceutical opioids in Australia: a protocol for a retrospective observational study.
    Nielsen S; Crossin R; Middleton M; Martin C; Wilson J; Lam T; Scott D; Smith K; Lubman D
    BMJ Open; 2019 May; 9(5):e029170. PubMed ID: 31138584
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combatting pain after orthopedic/trauma surgery- perioperative oral extended-release tapentadol vs. extended-release oxycodone/naloxone.
    Haeseler G; Schaefers D; Prison N; Ahrens J; Liu X; Karch A
    BMC Anesthesiol; 2017 Jul; 17(1):91. PubMed ID: 28693439
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Does tapentadol affect sex hormone concentrations differently from morphine and oxycodone? An initial assessment and possible implications for opioid-induced androgen deficiency.
    Eichenbaum G; Göhler K; Etropolski M; Steigerwald I; Pergolizzi J; Kim M; Vorsanger G
    J Opioid Manag; 2015; 11(3):211-27. PubMed ID: 25985806
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of discharge opioid on persistent postoperative opioid use: a retrospective cohort study comparing tapentadol with oxycodone.
    Lam T; Xia T; Biggs N; Treloar M; Cheng O; Kabu K; Stevens JA; Evans JD; da Gama ME; Lubman DI; Nielsen S
    Anaesthesia; 2023 Apr; 78(4):420-431. PubMed ID: 36535726
    [TBL] [Abstract][Full Text] [Related]  

  • 33. FDA approvals of generic drugs: impact on the diversion of opioid analgesics with a potential for abuse.
    Inciardi JA; Surratt HL; Stivers Y; Cicero TJ
    J Opioid Manag; 2009; 5(2):81-7. PubMed ID: 19507804
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bowel function after tapentadol and oxycodone immediate release (IR) treatment in patients with low back or osteoarthritis pain.
    Kwong WJ; Hammond G; Upmalis D; Okamoto A; Yang M; Kavanagh S
    Clin J Pain; 2013 Aug; 29(8):664-72. PubMed ID: 23835764
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A typology of people who tamper with pharmaceutical opioids: responses to introduction of a tamper-resistant formulation of controlled-release oxycodone.
    Peacock A; Degenhardt L; Larance B; Cama E; Lintzeris N; Ali R; Bruno R
    Pharmacoepidemiol Drug Saf; 2015 Dec; 24(12):1321-33. PubMed ID: 26419615
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Solution to Detect, Classify, and Report Illicit Online Marketing and Sales of Controlled Substances via Twitter: Using Machine Learning and Web Forensics to Combat Digital Opioid Access.
    Mackey T; Kalyanam J; Klugman J; Kuzmenko E; Gupta R
    J Med Internet Res; 2018 Apr; 20(4):e10029. PubMed ID: 29613851
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gastrointestinal Adverse Events in Hospitalized Patients Following Orthopedic Surgery: Tapentadol Immediate Release Versus Oxycodone Immediate Release.
    Wang X; Narayan SW; Penm J; Johnstone C; Patanwala AE
    Pain Physician; 2021 May; 24(3):E309-E315. PubMed ID: 33988952
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reduced abuse, therapeutic errors, and diversion following reformulation of extended-release oxycodone in 2010.
    Severtson SG; Bartelson BB; Davis JM; Muñoz A; Schneider MF; Chilcoat H; Coplan PM; Surratt H; Dart RC
    J Pain; 2013 Oct; 14(10):1122-30. PubMed ID: 23816949
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of Tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study.
    Afilalo M; Etropolski MS; Kuperwasser B; Kelly K; Okamoto A; Van Hove I; Steup A; Lange B; Rauschkolb C; Haeussler J
    Clin Drug Investig; 2010; 30(8):489-505. PubMed ID: 20586515
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Considerations for perioperative opioid analgesic stewardship in Australia: a focus on tapentadol.
    Ternel Lebret SC
    Pain Manag; 2023 May; 13(5):299-307. PubMed ID: 37291959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.